Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 970 Neoplasms 767 Carcinoma, Non-Small-Cell Lung 750 Prostatic Neoplasms 577 Colorectal Neoplasms 503 Lung Neoplasms 447 Neoplasm Metastasis 408 Multiple Myeloma 376 Leukemia, Myeloid, Acute 358 Ovarian Neoplasms 311 Pancreatic Neoplasms 306 Melanoma 275 Squamous Cell Carcinoma of Head and Neck 259 Recurrence 248 Carcinoma, Hepatocellular 233 Glioblastoma 225 Brain Neoplasms 221 Head and Neck Neoplasms 202 Triple Negative Breast Neoplasms 200 Carcinoma, Renal Cell 200 Lymphoma 192 Precursor Cell Lymphoblastic Leukemia-Lymphoma 191 Stomach Neoplasms 189 Endometrial Neoplasms 179 Lymphoma, Non-Hodgkin 175 Sarcoma 169 Glioma 168 Uterine Cervical Neoplasms 167 Lymphoma, Large B-Cell, Diffuse 160 Hematologic Neoplasms 159

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Ovarian Cancer Recurrent × 90 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡